Active Ingredient History

NOW
  • Now
PRIMAXIN® is a combination of cilastatin and imipenem. Cilastatin is a specific and reversible renal dehydropeptidase-I inhibitor. Imipenem is a penem antibacterial drug. Since the antibiotic, imipenem, is hydrolyzed by dehydropeptidase-I, which resides in the brush border of the renal tubule, cilastatin is administered with imipenem to block the metabolism and thus the inactivation of imipenem so that antibacterial levels of imipenem can be attained in the urine. However, cilastatin in and of itself does not have any antibacterial activity. It also prevents the metabolism of leukotriene D4 to leukotriene E4 through the inhibition of leukotriene D4 dipeptidase.   NCATS

  • SMILES: CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(=O)O)\C(=O)O
  • InChIKey: DHSUYTOATWAVLW-WFVMDLQDSA-N
  • Mol. Mass: 358.46
  • ALogP: 1.43
  • ChEMBL Molecules:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Combination drugs

( cilastatin (primaxin), imipenem (primaxin) - other name: imipenem and cilastatin )
|
( cilastatin (primaxin), relebactam (Recarbrio), imipenem (primaxin) - other name: imipenem/cilastatin/relebactam )
cilastatin | cilastatina | cilastatine | cilastatin, imipenem drug combination | cilastatin monosodium | cilastatin sodium | cilastatinum | cilastin | imipenem - cilastatin | imipenem + cilastatin | imipenem-cilastatin | imipenem-cilastatin, sodium salt | (l)-7-(2-amino-2-carboxy-ethylsulfanyl)-2-[(2,2-dimethyl-cyclopropanecarbonyl)-amino]-hept-2-enoic acid | mk 0787-mk 0791 mixture | mk 787-mk 791 mixture | mk-791 | primaxin | thienam | tienam 500 | (z)-7-((r)-2-amino-2-carboxy-ethylsulfanyl)-2-[((s)-2,2-dimethyl-cyclopropanecarbonyl)-amino]-hept-2-enoic acid | zienam | (z)-(s)-6-carboxy-6-[(s)-2,2-dimethylcyclopropanecarboxamido]hex-5-enyl-l-cysteine

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue